AU4570297A - Methods and apparatus for treatment of parkinson's disease - Google Patents
Methods and apparatus for treatment of parkinson's diseaseInfo
- Publication number
- AU4570297A AU4570297A AU45702/97A AU4570297A AU4570297A AU 4570297 A AU4570297 A AU 4570297A AU 45702/97 A AU45702/97 A AU 45702/97A AU 4570297 A AU4570297 A AU 4570297A AU 4570297 A AU4570297 A AU 4570297A
- Authority
- AU
- Australia
- Prior art keywords
- levodopa
- parkinson
- pharmaceutical composition
- disease
- transdermal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000018737 Parkinson disease Diseases 0.000 title claims description 32
- 238000011282 treatment Methods 0.000 title claims description 19
- 238000000034 method Methods 0.000 title claims description 14
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims description 76
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims description 75
- 229960004502 levodopa Drugs 0.000 claims description 74
- NULMGOSOSZBEQL-QMMMGPOBSA-N etilevodopa Chemical compound CCOC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 NULMGOSOSZBEQL-QMMMGPOBSA-N 0.000 claims description 29
- 229960001820 etilevodopa Drugs 0.000 claims description 29
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical group CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 27
- 238000009472 formulation Methods 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 23
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 16
- 229940079593 drug Drugs 0.000 claims description 15
- 238000003860 storage Methods 0.000 claims description 15
- 239000012530 fluid Substances 0.000 claims description 12
- 125000005907 alkyl ester group Chemical group 0.000 claims description 10
- 239000003599 detergent Substances 0.000 claims description 9
- 239000002904 solvent Substances 0.000 claims description 9
- 230000037317 transdermal delivery Effects 0.000 claims description 9
- 235000019260 propionic acid Nutrition 0.000 claims description 8
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims description 8
- 239000003125 aqueous solvent Substances 0.000 claims description 7
- 239000003623 enhancer Substances 0.000 claims description 7
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 6
- 230000003413 degradative effect Effects 0.000 claims description 6
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 claims description 6
- 229960003964 deoxycholic acid Drugs 0.000 claims description 6
- 239000007933 dermal patch Substances 0.000 claims description 6
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 6
- 229960004205 carbidopa Drugs 0.000 claims description 5
- TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 claims description 5
- 230000035515 penetration Effects 0.000 claims description 3
- 239000003381 stabilizer Substances 0.000 claims description 3
- 239000004141 Sodium laurylsulphate Substances 0.000 claims description 2
- 229940035678 anti-parkinson drug Drugs 0.000 claims description 2
- 238000004891 communication Methods 0.000 claims description 2
- 231100000252 nontoxic Toxicity 0.000 claims description 2
- 230000003000 nontoxic effect Effects 0.000 claims description 2
- 230000001105 regulatory effect Effects 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims 2
- 150000001735 carboxylic acids Chemical group 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 230000001276 controlling effect Effects 0.000 claims 1
- 239000002085 irritant Substances 0.000 claims 1
- 231100000021 irritant Toxicity 0.000 claims 1
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 23
- 239000000243 solution Substances 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 12
- 229960003638 dopamine Drugs 0.000 description 11
- 208000012661 Dyskinesia Diseases 0.000 description 9
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 7
- 230000036765 blood level Effects 0.000 description 7
- 238000001802 infusion Methods 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 206010030312 On and off phenomenon Diseases 0.000 description 6
- 238000013270 controlled release Methods 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 5
- 230000002411 adverse Effects 0.000 description 4
- 230000003291 dopaminomimetic effect Effects 0.000 description 4
- 229940083575 sodium dodecyl sulfate Drugs 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- 230000007850 degeneration Effects 0.000 description 3
- 230000036576 dermal application Effects 0.000 description 3
- 210000005064 dopaminergic neuron Anatomy 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 210000003523 substantia nigra Anatomy 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 208000014094 Dystonic disease Diseases 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 208000010118 dystonia Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000001577 neostriatum Anatomy 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000000153 supplemental effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- IVTMXOXVAHXCHI-YXLMWLKOSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid;(2s)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1.NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 IVTMXOXVAHXCHI-YXLMWLKOSA-N 0.000 description 1
- 102000003823 Aromatic-L-amino-acid decarboxylases Human genes 0.000 description 1
- 108090000121 Aromatic-L-amino-acid decarboxylases Proteins 0.000 description 1
- 241001573498 Compacta Species 0.000 description 1
- 208000035854 Drug effect decreased Diseases 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- -1 LD methyl ester Chemical class 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- UCQAPROAHYVQIS-UHFFFAOYSA-N butanoic acid;propan-1-ol Chemical compound CCCO.CCCC(O)=O UCQAPROAHYVQIS-UHFFFAOYSA-N 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- QDPJYNQBVLCKDB-UHFFFAOYSA-N dichloromethane;ethyl acetate;methanol;propan-2-one Chemical compound OC.ClCCl.CC(C)=O.CCOC(C)=O QDPJYNQBVLCKDB-UHFFFAOYSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229920002457 flexible plastic Polymers 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000001660 hyperkinetic effect Effects 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000003483 hypokinetic effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000008289 pathophysiological mechanism Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000009118 salvage therapy Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229940001089 sinemet Drugs 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU15537/02A AU768154B2 (en) | 1996-10-13 | 2002-02-11 | Treatment of Parkinson's disease |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL119417 | 1996-10-13 | ||
IL11941796A IL119417A (en) | 1996-10-13 | 1996-10-13 | Pharmaceutical composition for transdermal administration of levodopa for parkinson's disease |
PCT/IL1997/000327 WO1998016208A1 (en) | 1996-10-13 | 1997-10-09 | Methods and apparatus for treatment of parkinson's disease |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU15537/02A Division AU768154B2 (en) | 1996-10-13 | 2002-02-11 | Treatment of Parkinson's disease |
Publications (1)
Publication Number | Publication Date |
---|---|
AU4570297A true AU4570297A (en) | 1998-05-11 |
Family
ID=11069375
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU45702/97A Abandoned AU4570297A (en) | 1996-10-13 | 1997-10-09 | Methods and apparatus for treatment of parkinson's disease |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1011644A4 (ja) |
JP (2) | JP2002513389A (ja) |
AU (1) | AU4570297A (ja) |
CA (1) | CA2268455C (ja) |
IL (1) | IL119417A (ja) |
WO (1) | WO1998016208A1 (ja) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6746688B1 (en) | 1996-10-13 | 2004-06-08 | Neuroderm Ltd. | Apparatus for the transdermal treatment of Parkinson's disease |
IL119417A (en) * | 1996-10-13 | 2003-02-12 | Moshe Kushnir | Pharmaceutical composition for transdermal administration of levodopa for parkinson's disease |
AU1681799A (en) * | 1997-12-17 | 1999-07-05 | Sekisui Chemical Co., Ltd. | Percutaneously absorbable levodopa-containing preparation |
AU5409699A (en) * | 1999-07-05 | 2001-01-22 | Idea Ag | A method for the improvement of transport across adaptable semi-permeable barriers |
US7858112B2 (en) | 2002-02-28 | 2010-12-28 | Lintec Corporation | Percutaneous absorption system and percutaneous absorption method |
JP4608187B2 (ja) * | 2002-02-28 | 2011-01-05 | リンテック株式会社 | 経皮吸収型製剤 |
DE10261807A1 (de) * | 2002-12-19 | 2004-07-01 | Turicum Drug Development Ag | Deuterierte Catecholaminderivate sowie diese Verbindungen enthaltende Arzneimittel |
US8815950B2 (en) | 2003-08-29 | 2014-08-26 | Janssen Biotech, Inc. | Pharmaceutical compositions and method of using levodopa and carbidopa |
AT500095B8 (de) * | 2004-01-23 | 2007-02-15 | Braun Werner Mag | Transdermales abgabesystem |
JP2009532346A (ja) * | 2006-03-31 | 2009-09-10 | イラスマス・ユニバーシティ・メディカル・センター・ロッテルダム | 腫瘍増殖制御のための新規組成物 |
ES2660772T3 (es) * | 2010-11-15 | 2018-03-26 | Neuroderm Ltd | Administración continua de L-dopa, inhibidores de dopa descarboxilasa, inhibidores de catecol-o-metil transferasa y composiciones para ello |
BR112013014304A2 (pt) * | 2010-12-10 | 2016-07-19 | Synagile Corp | composições de pró-fármaco levodopa infundíveis subcutaneamente e método de infusão |
EP3777833B1 (en) | 2014-03-13 | 2023-10-18 | Neuroderm Ltd. | Dopa decarboxylase inhibitor compositions |
US10258585B2 (en) | 2014-03-13 | 2019-04-16 | Neuroderm, Ltd. | DOPA decarboxylase inhibitor compositions |
CN107848954A (zh) | 2015-03-30 | 2018-03-27 | 伯里兰有限责任公司 | 水溶性l‑dopa酯 |
DK3075723T3 (en) * | 2015-03-30 | 2017-09-11 | Berlirem Gmbh | High-resolution L-DOPA glycerol esters |
JP6982870B2 (ja) | 2015-05-06 | 2021-12-17 | シンアジャル コーポレイション | 薬物粒子を含有する医薬懸濁液、それらの投与のためのデバイス、およびそれらの使用方法 |
US11844754B2 (en) | 2020-11-17 | 2023-12-19 | Neuroderm, Ltd. | Methods for treatment of Parkinson's disease |
US11331293B1 (en) | 2020-11-17 | 2022-05-17 | Neuroderm, Ltd. | Method for treatment of Parkinson's disease |
US11213502B1 (en) | 2020-11-17 | 2022-01-04 | Neuroderm, Ltd. | Method for treatment of parkinson's disease |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3779500T2 (de) * | 1986-06-10 | 1993-01-21 | Chiesi Farma Spa | Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen. |
US5474783A (en) * | 1988-03-04 | 1995-12-12 | Noven Pharmaceuticals, Inc. | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
GB8807504D0 (en) * | 1988-03-29 | 1988-05-05 | Sandoz Ltd | Improvements in/relating to organic compounds |
US4927408A (en) * | 1988-10-03 | 1990-05-22 | Alza Corporation | Electrotransport transdermal system |
JPH04261119A (ja) * | 1991-02-13 | 1992-09-17 | Lintec Corp | 経皮吸収型貼付剤 |
US5354885A (en) * | 1992-12-24 | 1994-10-11 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Process for preparing ethyl ester of L-DOPA |
IL111240A (en) * | 1993-10-18 | 2001-10-31 | Teva Pharma | Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them |
IL119417A (en) * | 1996-10-13 | 2003-02-12 | Moshe Kushnir | Pharmaceutical composition for transdermal administration of levodopa for parkinson's disease |
-
1996
- 1996-10-13 IL IL11941796A patent/IL119417A/xx not_active IP Right Cessation
-
1997
- 1997-10-09 WO PCT/IL1997/000327 patent/WO1998016208A1/en active Application Filing
- 1997-10-09 JP JP51815198A patent/JP2002513389A/ja active Pending
- 1997-10-09 EP EP97944077A patent/EP1011644A4/en not_active Withdrawn
- 1997-10-09 AU AU45702/97A patent/AU4570297A/en not_active Abandoned
- 1997-10-09 CA CA002268455A patent/CA2268455C/en not_active Expired - Fee Related
-
2008
- 2008-08-11 JP JP2008207049A patent/JP2009001588A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CA2268455C (en) | 2007-05-15 |
IL119417A0 (en) | 1997-01-10 |
EP1011644A1 (en) | 2000-06-28 |
WO1998016208A1 (en) | 1998-04-23 |
CA2268455A1 (en) | 1998-04-23 |
JP2009001588A (ja) | 2009-01-08 |
JP2002513389A (ja) | 2002-05-08 |
EP1011644A4 (en) | 2006-02-08 |
IL119417A (en) | 2003-02-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6746688B1 (en) | Apparatus for the transdermal treatment of Parkinson's disease | |
CA2268455C (en) | Methods and apparatus for treatment of parkinson's disease | |
US20230047523A1 (en) | Continuous Administration of L-Dopa, Dopa Decarboxylase Inhibitors, Catechol-O-Methyl Transferase Inhibitors and Compositions for Same | |
CA2574437C (en) | Infusion and injection solution of levodopa | |
PT2432454T (pt) | Composições para administração contínua de inibidores de dopa decarboxilase | |
US6166081A (en) | Methods and apparatus for treatment of Parkinson's disease | |
CN111701024B (zh) | 一种左旋多巴制剂及其制备方法及其应用 | |
AU768154B2 (en) | Treatment of Parkinson's disease | |
Obeso et al. | Continuous dopaminergic stimulation in Parkinson's disease | |
CN111643493B (zh) | 一种高浓度左旋多巴制剂及其制备方法及其应用 | |
EP3453388B1 (en) | Pharmaceutical solution comprising dopamine hydrochloride | |
CA3097629A1 (en) | Compositions and methods of use thereof to promote muscle growth and function | |
Schelosky et al. | Current strategies in the drug treatment of advanced Parkinson's disease—new modes of dopamine substitution | |
CN112656791A (zh) | 一种治疗枫糖尿病的化合物 | |
Obeso et al. | New Routes of Administration for Antiparkinsonian Therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |